2010 global sales reached US $ 850 billion in drug market

Bio-generic drugs have the opportunity to become medical focus of most attention in recent years. A set of data is the most eye-catching: 2010 global sales reached US $ 850 billion in drug market, where biotechnology drugs and generic drugs and record, reached US $ 140 billion and $ 120 billion, respectively. In the United States outside of bio-generic drug sales also exceeded 1US $ 0. November 25, organised by the biological effects of bio-generics Summit Forum held in Shanghai, Forum around the "bio-pharmaceutical industry trends and key technologies-like" and other topics for in-depth discussion and analysis of comprehensive interpretation. Experts believe that in 2013, 2014, a group of bio-pharmaceutical patents expire will focus. United States FDA for bio-generic drugsRegulations to be announced, and heralded the bio-generics in the next 5-10 year will usher in a significant development opportunity. Experts said China has licensed 13 25 382 different specifications of the products of genetic engineering medicine and genetic engineering vaccine, only 6 9 21 specifications of products belonging to the original, the rest belongs to the clone. In the listed company, hisun pharmaceutical(600,267 valuation, assessment, quotes, news the old republic power leveling, the major trading) hand in hand with Pfizer, the first sign of joint moshadong of the drugs industry, fosun pharmaceutical (600,196 valuation, assessment, quotes, news, the major trading) and Longshan Group marriage, were seen as representatives of domestic business of bio-generics. It is learnt that the bio-generic drug research and development in our country has a certain basis. ToA case study of Shanghai swtor power leveling, has, huaxin biology, Shanghai Institute of biological products Wanxing bio and other 7 companies have drugs such as interferon, human growth hormone. According to the Shanghai Municipal Deputy Director Fu Daxu bio-medicine industry promotion center of science and technology introduction, "Twelve-Five" period of recombinant cytokine drugs and biological treatment of industrial development will focus on the innovation of new targets for gene engineering cellFactor, somatic cell therapy and gene therapy studies. Technology Division Technical Advisor Li Xiangming, research fellow of Chinese bio-imitation pharmaceutical companies make recommendations, before the patent expires, ahead of layout of imitation and increasing indications are the bio-generics opportunity. But whether companies had the opportunity, also is to see whether there are patents, core technology. Ka and bio-pharmaceutical industry limited strategic cooperation in totalCommissioner Chen Rulei told reporters, according to an authoritative figures released by the forecasters by 2021 the global bio-generic drug to reach 250 billion dollars. He also said that technically successful, ranging from commercial success, especially in bio-pharmaceutical area as a whole. Don't just focus on the technical level, market sales and channels is also vital, to have a marketing effort, businessOn track to success. Chinese medicine (600,056 valuation, assessment, quotes, news, the major trading) Rui Guozhong, Director of science and technology achievements transformation Center reminds, domestic drug innovation, must consider good business ideas, and innovations in the market, is not available for innovation, innovation, innovation for the business. CIC securities believes that specifications such as bio-generic drug market in Europe and is growing rapidly, Including recombinant proteins and monoclonal antibody drugs to bio-generic drug industry brought huge development space. Gold-line statement: Gold-line reproduced above, does not indicate that confirm the description for investor use only and does not constitute investment advice. Investors a basis for action, at your own risk.